Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation

27 Apr 2021

Abstract excerpt

Ivacaftor has been shown to restore the functionality of the S1251N (also known as c.3752G>A) mutated CFTR, which may cause alterations in both airway and gut physiology and micro-environment, resulting in a change of microbiota in these organs. The aim of the present study was to analyze the effects of ivacaftor on the microbial community composition of both airway and gut in subjects with CF carrying one S1251N...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis Research Advances
Share to Pediatric health and respiratory diseases
Share to Tracheal and airway disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33925519
DOI: 10.3390/jpm11050350

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N MutationPMID 33925519Read ↗

Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.Semantic proximity Read ↗

Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.Semantic proximity Read ↗

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal InflammationSemantic proximity Read ↗

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosisSemantic proximity Read ↗

Remodelling of cystic fibrosis respiratory microbiota in response to extended Elexacaftor–Tezacaftor–Ivacaftor therapySemantic proximity Read ↗

Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-IvacaftorSemantic proximity Read ↗

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.Semantic proximity Read ↗

The altered gut microbiota in adults with cystic fibrosis.Semantic proximity Read ↗

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.Semantic proximity Read ↗

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With IvacaftorSemantic proximity Read ↗

Modulation, microbiota and inflammation in the adult CF gut: A prospective study.Semantic proximity Read ↗

Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.